455 related articles for article (PubMed ID: 23955585)
1. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.
Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E
Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585
[TBL] [Abstract][Full Text] [Related]
2. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Alberts SR; Horvath WL; Sternfeld WC; Goldberg RM; Mahoney MR; Dakhil SR; Levitt R; Rowland K; Nair S; Sargent DJ; Donohue JH
J Clin Oncol; 2005 Dec; 23(36):9243-9. PubMed ID: 16230673
[TBL] [Abstract][Full Text] [Related]
4. Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?
Reddy SK; Tsung A; Marsh JW; Geller DA
J Surg Oncol; 2012 Jan; 105(1):55-9. PubMed ID: 21842519
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival.
Beppu T; Miyamoto Y; Sakamoto Y; Imai K; Nitta H; Hayashi H; Chikamoto A; Watanabe M; Ishiko T; Baba H
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S405-13. PubMed ID: 24570379
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
Uetake H; Yasuno M; Ishiguro M; Kameoka S; Shimada Y; Takahashi K; Watanabe T; Muro K; Baba H; Yamamoto J; Mizunuma N; Tamagawa H; Mochizuki I; Kinugasa Y; Kikuchi T; Sugihara K
Ann Surg Oncol; 2015 Mar; 22(3):908-15. PubMed ID: 25465375
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
[TBL] [Abstract][Full Text] [Related]
9. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
10. Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases.
Galizia G; De Vita F; Lieto E; Zamboli A; Morgillo F; Castellano P; Mabilia A; Auricchio A; Renda A; Ciardiello F; Orditura M
Oncol Rep; 2013 Dec; 30(6):2992-8. PubMed ID: 24126855
[TBL] [Abstract][Full Text] [Related]
11. [Specific treatment situations in metastatic colorectal cancer].
Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
[TBL] [Abstract][Full Text] [Related]
12. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer.
Araujo R; Gonen M; Allen P; Blumgart L; DeMatteo R; Fong Y; Kemeny N; Jarnagin W; D'Angelica M
Ann Surg Oncol; 2013 Dec; 20(13):4312-21. PubMed ID: 23897009
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and treatment of colorectal liver metastases - workflow].
Grundmann RT; Hermanek P; Merkel S; Germer CT; Grundmann RT; Hauss J; Henne-Bruns D; Herfarth K; Hermanek P; Hopt UT; Junginger T; Klar E; Klempnauer J; Knapp WH; Kraus M; Lang H; Link KH; Löhe F; Merkel S; Oldhafer KJ; Raab HR; Rau HG; Reinacher-Schick A; Ricke J; Roder J; Schäfer AO; Schlitt HJ; Schön MR; Stippel D; Tannapfel A; Tatsch K; Vogl TJ;
Zentralbl Chir; 2008 Jun; 133(3):267-84. PubMed ID: 18563694
[TBL] [Abstract][Full Text] [Related]
14. Impact of margin status and neoadjuvant chemotherapy on survival, recurrence after liver resection for colorectal liver metastasis.
Pandanaboyana S; White A; Pathak S; Hidalgo EL; Toogood G; Lodge JP; Prasad KR
Ann Surg Oncol; 2015 Jan; 22(1):173-9. PubMed ID: 25084766
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
[TBL] [Abstract][Full Text] [Related]
16. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
[TBL] [Abstract][Full Text] [Related]
17. High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
Phelip JM; Mineur L; De la Fouchardière C; Chatelut E; Quesada JL; Roblin X; Pezet D; Mendoza C; Buc E; Rivoire M
Ann Surg Oncol; 2016 Jul; 23(7):2161-6. PubMed ID: 26739304
[TBL] [Abstract][Full Text] [Related]
18. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
[TBL] [Abstract][Full Text] [Related]
19. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
